RxDoctor Payments Data

Christopher Christian, MD

Psychiatry · Milwaukee, WINPI 1821261272

Payments from drug & device makers

$921in general payments, 2019–2025

Across 47 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$170
  • Johnson & Johnson$152
  • Otsuka America Pharmaceutical, Inc.$131
  • Indivior Inc.$96
  • AbbVie$80
  • E.r. Squibb & Sons, L.L.C.$57
  • plus $235 from 8 others

What the payments were for

  • Food & beverage$921100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$921 in reported general payments places this provider in the 80th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$14,261
Medicare patients
57
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate18$163,393
VraylarCariprazine Hcl103$157,081
IngrezzaValbenazine Tosylate18$153,829
SublocadeBuprenorphine32$69,262
Invega SustennaPaliperidone Palmitate13$46,542
CaplytaLumateperone Tosylate26$45,188
RexultiBrexpiprazole25$38,795
TrintellixVortioxetine Hydrobromide76$37,266
VyvanseLisdexamfetamine Dimesylate44$24,355
Clozapine288$17,139
Risperdal ConstaRisperidone Microspheres26$16,073
SuboxoneBuprenorphine Hcl/Naloxone Hcl34$14,260
AuvelityDextromethorphan Hbr/Bupropion12$13,435
Adderall XrDextroamphetamine/Amphetamine17$9,739
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl42$7,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta, Concerta$152$232,05971 claims
AbbVieVraylar$80$157,081103 claims
Neurocrine Biosciences, Inc.Ingrezza$14$153,82918 claims
Indivior Inc.Sublocade, Suboxone$96$83,52266 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$17$61,621120 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$49$45,18826 claims
Otsuka America Pharmaceutical, Inc.Rexulti$131$38,79525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →